Getting TiME on your side.
Turning colorful insight into meaningful impact.

REQUEST A DEMO

Revealing actionable biology with multiplex immunofluorescence

Ultivue seeks to make the promise of immuno-therapy a reality for every patient through rapid, precision profiling of tumor biology.

Multiplexing now gives you the power to visualize several biomarkers at once, enabling researchers to quickly elucidate the complex phenotypes of the tumor immune microenvironment (TiME) and advance research discoveries.

Reduce TAT in the lab by developing tailored optimized assays that can be applied to a broad range of cancer types and indications to characterize immune contexture.

CD8-labeled
IHC

CD3, Granzyme B,
SOX-10, DAPI

Cytotoxic T-cell mediated melanoma tumor cell death. In comparison to the limited information from single stain IHC (Left), Multiplexed Immunofluorescence (mIF) can capture an actionable biological event affording disease insight with spatial resolution. Here T cells demonstrate an immune response by recognizing and preparing to kill neighboring tumor cells: CD3-labeled T cells are seen releasing GrzB near SOX-10 labeled tumor cells.

Designed with translational researchers and pathologists in mind.

H&E

CD8, CD68, PD-L1, PanCK, DAPI

Co-registered stacked image of mIF

Whole Slide Scan ROI

Pathologists

Streamlined workflow
Whole-slide imaging
Non-disruptive staining
Same slide H&E compatible

Researchers

Rapid assay development
Fully customizable biomarkers
Uncover complex phenotypes
Advanced image analysis

Don’t go it alone: leveraging partnerships

Ultivue and its valued partners have established a seamless workflow integrating validated antibodies, state of the art chemistry and advanced analytics to drive personalized medicine.

With Ultivue, you know you’re getting the industry’s best at every step.

Antibodies

Abcam

Bethyl

Cell Signaling

Thermo Fisher

Stainers

Leica

Scanners

Olympus

Leica

Zeiss

Analysis

Indica Labs

VisioPharm

CRO's

Indivumed

OracleBio

Targos

Send us your sample, we’ll stain and analyze it for you.

VUEfinder Gallery

See for yourself

Ultivue is making an impact

Check out our catalogue of peer-reviewed publications and scientific presentations

PUBLICATIONS

Kaiso (ZBTB33) subcellular partitioning functionally links LC3A/B, the tumor microenvironment, and breast cancer survival


-Nat. Commun. Biology 2021

Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial


-Vaccines (Basel) 2020

Improving the Diagnostic Accuracy of the PD-L1 Test with Image Analysis and Multiplex Hybridization

Cancers 2020, 12(5), 1114; https://doi.org/10.3390/cancers12051114

SEE ALL PUBLICATIONS

POSTERS

Gene Expression Profiling, Digital Spatial Profiling and Multiplex Immunohistochemistry of the Tumor-immune Microenvironment in HNSCC Tumors

-Covance, AACR 2020

Measuring concordance of CD8 and PD-L1 expression in Non-Small Cell Lung cancer between a novel multiplex immunofluorescence assay and a brightfield laboratory developed test

-Ultivue, AACR 2020

Utilizing Image Analysis to Characterize an 8-plex Immunofluorescence Immune Checkpoint Biomarker Panel within the Tumor Tissue Microenvironment

-Oracle Bio, AACR 2020

SEE ALL POSTERS

WEBINARS

Investigating Targeted CD3 Activation in Cytotoxic T cells via Immune Checkpoint Inhibition

-The Scientist, 2020

Improving the diagnostic accuracy of the PD-L1 test with multiplexing and image analysis

-Queens University Belfast, 2020

Combinatorial Immunotherapy Approaches for Patients with Advanced Solid Tumors

-GEN & Clinical Omics, 2021

SEE ALL WEBINARS
Contact Us